CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING EXPENSES
General and administrative	$ 229	$ 113
Research and development	301	267
Total operating expenses	530	380
Interest and other expenses, net	60	15
Loss from operations before taxes	590	395
Income tax benefit	(3)	(8)
Net Loss	587	387
Less: Net Loss attributable to the noncontrolling interest	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 587	$ 387
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders	$ 0.01	$ 0.01
Basic and diluted shares outstanding	54,385	40,885